_______________________________________________________________________________________________________________
OXB dominated discussions. Those conversations continue, but they no longer define the entire landscape.“ If I look at the business today, the conversation is much broader. Alongside lentiviral vectors, we’ re working across AAV, measles, MVA, and other platforms. Oncology remains a major area of activity, but we’ re also supporting programs in ophthalmology, dermatology, neurology, and a growing range of other indications.”
The diversification is changing both the type of work entering OXB and the stage at which customers engage with the business. For Sébastien, evidence of that shift is in the numbers.“ We’ re seeing more than 30 percent growth in project volumes compared with last year. It’ s not just coming from early-stage work such as process development and Phase I manufacturing. We’ re also seeing strong growth in late-stage and commercial manufacturing.”
That mix may be one of the clearest indicators of where the company is headed. More programs are progressing
through development. More customers are preparing for commercialization. And more manufacturing activity now ties directly to product launches.
As OXB looks toward 2027, that reality is shaping priorities across the business.“ We expect several product launches over the next 12 months, with the latest currently scheduled for Q3 2027.” Preparing for those launches means continuing the US ramp-up, expanding manufacturing capabilities across the network, and ensuring facilities are ready to support increasing demand. It means delivering larger AAV programs from the UK while maintaining the consistency customers expect across every site.
For a company once defined largely by its platform technologies, the focus has shifted. Today’ s conversation is less about what OXB can invent and more about what it can deliver as therapies move closer to patients. ■
www. oxb. com
manufacturing-today. com 125